Rothschild raises target for Abbott Laboratories stock to USD 127.00
Published on 10/15/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting dates
- Rothschild Redburn raised its Abbott target to USD 127.00 on October 2, 2026.
- Second-quarter revenue reached USD 12.59 billion, up 13.00 percent year over year.
- Abbott Laboratories stock traded at EUR 92.35 at 9:37 a.m. CEST at Lang & Schwarz on October 15, 2026, minus 0.03 percent versus the Xetra close of October 14, 2026.
Abbott Laboratories (ISIN US0028241000) received a higher USD 127.00 price target from Rothschild Redburn on October 2, 2026, up from USD 119.00, alongside an upgrade from Neutral to Buy, as Investing.com reported. The call puts Abbott's medical-device growth against a demanding earnings test before the next quarterly report.
Why the target moved higher
Rothschild Redburn cited Abbott's Medical Devices business and projected 10.60 percent organic growth for fiscal year 2026. The same report said diabetes technologies could grow 11.70 percent in fiscal year 2026, while the acquisition of Exact Sciences strengthened Abbott's cancer-diagnostics position.
Abbott's second-quarter 2026 revenue reached USD 12.59 billion, a 13.00 percent increase from the second quarter of 2025. Consolidated net income was USD 928.00 million and diluted GAAP earnings per share were USD 0.53 for the quarter ended June 30, 2026. The figures come from Abbott's reported financial statements, while Investing.com reported adjusted earnings per share of USD 1.31 and the same revenue figure.
Three dates explain the setup
On July 16, 2026, Abbott reported second-quarter adjusted earnings per share of USD 1.31 and revenue of USD 12.59 billion, according to MarketBeat. On October 1, 2026, Abbott began US commercial sales of SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening, as reported by Simply Wall St. On October 2, 2026, Rothschild Redburn raised its target from USD 119.00 to USD 127.00.
When are the next milestones?
Abbott's next quarterly results are scheduled for October 21, 2026, before the market opens, with company guidance of USD 1.38 to USD 1.46 for adjusted earnings per share and consensus revenue of USD 13.00 billion, according to MarketBeat. October 15, 2026 is the ex-dividend date for Abbott's USD 0.63 quarterly dividend, which is scheduled for payment on November 16, 2026.
Stock stays near the Xetra close
Abbott Laboratories stock was trading at EUR 92.35 at Lang & Schwarz on October 15, 2026 at 9:37 a.m. CEST, minus 0.03 percent versus the Xetra close of October 14, 2026 at EUR 92.38. The euro 52-week range stood at EUR 70.10 to EUR 116.00 as of October 15, 2026.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock facts
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 9:37 a.m. CEST): EUR 92.35
- Change versus Xetra close: minus 0.03 percent
- Xetra close (October 14, 2026): EUR 92.38
- 52-week range: EUR 70.10-EUR 116.00 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
